DelveInsight’s ‘Irritable Bowel Syndrome Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Irritable Bowel Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Irritable Bowel Syndrome pipeline domain.

 

Irritable Bowel Syndrome Overview

Irritable Bowel Syndrome is a chronic, often debilitating, functional gastrointestinal disorder. It can begin in childhood, adolescence, or adulthood and can resolve unexpectedly for periods throughout  an individual’s lifespan, recurring at any age. The condition causes recurrent attacks of abdominal pain or discomfort in association with bowel habits. 

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years. Irritable Bowel Syndrome Key players such as – P4Microbiome,Biomica, Cosmo Pharmaceuticals, RaQualia Pharma, Invea Therapeutics, Inc. RedHill Biopharma, 4D pharma , and others, are developing therapies for the Irritable Bowel Syndrome treatment 
• Irritable Bowel Syndrome Emerging therapies such as – BMC426, RHB-102, Blautix, Rifamycin-MMX, INVA 8002, RQ-00310941, P4M01, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.

Discover more about the emerging Irritable Bowel Syndrome drugs @ Irritable Bowel Syndrome Treatment Drugs

Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include: 

• RHB-102: RedHill Biopharma Ltd.
• P4M01: P4Microbiome
• INVA 8002: Invea Therapeutics, Inc.
• Blautix: 4D pharma
• BMC426: Biomica
• RQ-00310941: RaQualia Pharma
• Rifamycin SV-MMX: Cosmo Pharmaceuticals

Irritable Bowel Syndrome Pipeline Analysis:

The Irritable Bowel Syndrome pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Irritable Bowel Syndrome treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.
• Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Irritable Bowel Syndrome Market Drivers

• Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit
• Surge in the level of Unhealthy Lifestyle

Irritable Bowel Syndrome Market Barriers

• Complex Irritable Bowel Syndrome diagnostic process
• Lack of Irritable Bowel Syndrome awareness

Find out more about the Irritable Bowel Syndrome treatment options in development @ Irritable Bowel Syndrome Clinical Trials

Scope of Irritable Bowel Syndrome Pipeline Drug Insight    

• Coverage: Global
• Key Irritable Bowel Syndrome Companies: P4Microbiome,Biomica, Cosmo Pharmaceuticals, RaQualia Pharma, Invea Therapeutics, Inc. RedHill Biopharma, 4D pharma , and others
• Key Irritable Bowel Syndrome Therapies: BMC426, RHB-102, Blautix, Rifamycin-MMX, INVA 8002, RQ-00310941, P4M01, and others
• Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
• Irritable Bowel Syndrome Market Dynamics:  Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers 

Table of Contents

1. Introduction

2. Executive Summary

3. Irritable Bowel Syndrome Overview

4. Irritable Bowel Syndrome Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Irritable Bowel Syndrome Therapeutic Assessment

11. Irritable Bowel Syndrome Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Irritable Bowel Syndrome Unmet Needs

14. Irritable Bowel Syndrome Market Drivers and Irritable Bowel Syndrome Market Barriers

15. Appendix

16. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com